| Hans-Günter Meyer-Thompson | International
USA. FDA and SAMHSA issue joint letter clarifying buprenorphine prescribing recommendations
USA. FDA and SAMHSA issue joint letter clarifying buprenorphine prescribing recommendations
Today, the U.S. Food and Drug Administration and the Substance Abuse and Mental Health Services Administration issued a joint letter affirming both agencies’ commitment to addressing the overdose crises by reducing barriers to accessing evidence-based treatments and providing person-centered care for substance use disorders. (U.S. Food and Drug Administration and the Substance Abuse and Mental Health Services Administration, USA, 09.05.2023)
https://www.samhsa.gov/sites/default/files/dear-colleague-letter-fda-samhsa.pdf